title: Angiotensin receptor blockade not related to history of dry eye symptoms and treatment in The Diabetic Retinopathy Candesartan Trials (DIRECT).
authors.forename: Scot E
authors.initials: SE
authors.lastname: Moss
authors.forename: Ronald
authors.initials: R
authors.lastname: Klein
authors.forename: Anne Katrin
authors.initials: AK
authors.lastname: Sjølie
authors.forename: Nish
authors.initials: N
authors.lastname: Chaturvedi
authors.forename: Anders R
authors.initials: AR
authors.lastname: Malm
authors.forename: John H
authors.initials: JH
authors.lastname: Fuller
authors.forename: Massimo
authors.initials: M
authors.lastname: Porta
mesh_terms: D000328:Adult; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000209:etiology; D004311:Double-Blind Method; D015352:Dry Eye Syndromes / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D011795:Surveys and Questionnaires; D013777:Tetrazoles / Q000627:therapeutic use*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D009883:Ophthalmic Solutions; D013777:Tetrazoles; C081643:candesartan